AGLP-1 na Melhoria da Qualidade do Sono de Pessoas com Excesso de Peso: Revisão Sistemática

Valérya Karolline Santos Sousa; Erica Costa Leal; José Cláudio Garcia Lira Neto; Maria Augusta Rocha Bezerra; Rutielle Ferreira Silva; Mychelangela de Assis Brito; Ruth Cardoso Rocha; Ana Lívia Castelo Branco de Oliveira

doi:10.36489/nursing.2026v31i332p12714-12737

Authors

Valérya Karolline Santos Sousa Graduanda em enfermagem pela Universidade Federal do Piauí. https://orcid.org/0000-0001-5542-962X
Erica Costa Leal Graduanda em enfermagem pela Universidade Federal do Piauí. https://orcid.org/0000-0002-6698-6816
José Cláudio Garcia Lira Neto Doutor em enfermagem; Universidade Federal do Piauí. https://orcid.org/0000-0003-2777-1406
Maria Augusta Rocha Bezerra Doutora em enfermagem; Universidade Federal do Piauí. https://orcid.org/0000-0003-0472-1852
Rutielle Ferreira Silva Doutora em enfermagem; Universidade Federal do Piauí. Graduanda em enfermagem pela Universidade Federal do Piauí. https://orcid.org/0000-0003-3630-5597
Mychelangela de Assis Brito Doutora em enfermagem; Universidade Federal do Piauí. https://orcid.org/0000-0002-4519-9979
Ruth Cardoso Rocha Doutora em enfermagem; Universidade Federal do Piauí. https://orcid.org/0000-0001-6702-6844
Ana Lívia Castelo Branco de Oliveira Doutora em enfermagem; Universidade Federal do Piauí. https://orcid.org/0000-0002-2634-0594

DOI:

https://doi.org/10.36489/nursing.2026v31i332p12714-12737

Keywords:

Glucagon-like Peptide-1 Receptor Agonists, Overweight, Sleep Quality

Abstract

Objective: To analyze the literature on the effectiveness of using GLP-1 in improving sleep quality in overweight individuals. Method: Systematic review conducted in the PubMed, LILACS, BDENF, CINAHL, COCHRANE, Web of Science, Embase, and Scopus databases in September 2025, in Portuguese, English, and Spanish. The risk of bias was analyzed using the Risk of Bias 2.0 tool. Results: Of the 32 studies identified, 7 comprised the final sample. The use of aGLP-1 promoted weight loss, which led to a decrease in the Apnea-Hypopnea Index, as well as an increase in minimum oxygen saturation. An improvement in subjective sleep quality was reported. However, in some studies, the
Epworth Sleepiness Scale did not show a statistically significant difference between the groups. Conclusion: GLP-1 agonists are promising for treating apnea and improving sleep in obese individuals through weight loss, although they have inconclusive effects on daytime sleepiness.

Metrics

Metrics Loading ...

References

LIMA MA, et al. Apnéia do sono: as consequências de uma doença silenciosa e perigosa. Braz J Health Rev. 2023;6(5):22181-8.

GOTTLIEB DJ, PUNJABI NM. Diagnosis and Management of Obstructive Sleep Apnea. JAMA. 2020;323(14):1389.

American Academy of Sleep Medicine. Hidden health crisis costing America billions: underdiagnosing and undertreating obstructive sleep apnea draining healthcare system [Internet]. Darien (IL): AASM; 2016 [citado 2025 Out 30]. Disponível em: https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf

ORGANIZAÇÃO MUNDIAL DA SAÚDE. Obesity [Internet]. Genebra: Organização Mundial da Saúde; 2023 [citado 2025 Out 15]. Disponível em: https://www.who.int/health-topics/obesity/#tab=tab_1

WORLD HEALTH ORGANIZATION (WHO). Obesity and overweight [Internet]. Genebra: WHO; 2021 [citado 2025 Ago 3]. Disponível em: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

MELO SP DA S DE C, et al. Sobrepeso, obesidade e fatores associados aos adultos em uma área urbana carente do Nordeste Brasileiro. Rev Bras Epidemiol. 2020;23.

DICKERSON RN, et al. Obesity and critical care nutrition: current practice gaps and directions for future research. Crit Care. 2022;26:283. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36127715/

WRIGHT EE, ARODA VR. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgrad Med. 2020;132(2):26-36.

PAGE MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.

Cochrane Bias Methods Group. RoB 2: a revised tool for assessing risk of bias in randomised trials [Internet]. [Local desconhecido]: Risk of Bias; 2019 [citado 2025 Out 28]. Disponível em: https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2

STRETTON B, et al. Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Intern Med J. 2023;53(8):1311-20.

NOLEN-DOERR E, STOCKMAN M-C, RIZO I. Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. Curr Obes Rep. 2019;8(3):284-91.

JIANG W, et al. Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath. 2023;27(5):1687-94.

SPRUNG VS, et al. Randomised, Controlled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA)(ROMANCE): Study protocol assessing the effects of weight loss on the apnea–hypnoea index (AHI). BMJ Open. 2020;10(7):e038856.

MALHOTRA A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-205.

Blackman A, O’Keeffe T, Al-Sherif M, Al-Sabti M, Al-Ansari A. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40(8):1310–9.

KANU C, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med. 2025;106719.

DOGAN ADA, et al. Effects of Treatment with Liraglutide on Health-Related Quality of Life and Obstructive Sleep Apnea in People with Obesity and Chronic Obstructive Pulmonary Disease. Research Square. 2022.

SONG Z, et al. Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis. Pharmaceuticals. 2025;18(9):1261. DOI: 10.3390/ph18091261.